Another promising therapeutic target might be cathepsin K. Cabozantinib, a tyrosine kinase receptor inhibitor that targets VEGFR and MET, has been shown to reduce cathepsin K activity, suggesting its potential usefulness in the targeted treatment of cathepsin K-positive TFE3-rearranged renal cell carcinoma [38,100]. This evidence concerns the gene TFE3 and renal cell carcinoma.